Devonian Health Group Inc. GSD.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · groupedevonian.com
Devonian Health Group Inc. is a Quebec-based clinical-stage pharmaceutical company specializing in the development of botanical drugs derived from plant materials and algae for the treatment of autoimmune and fibroinflammatory conditions. Its lead product candidate Thykamine is in clinical trials for atopic dermatitis and ulcerative colitis, utilizing the company's proprietary extraction and stabilization technology.
Key ratios
FreeCashFlowOnSale TTM -0.95
FreeCashFlowOnSale 2025 -0.05
FreeCashFlowOnSale 2024 0.29
FreeCashFlowOnSale 2023 -1.86
NetIncomeMargin TTM -0.88
NetIncomeMargin 2025 -0.25
NetIncomeMargin 2024 -0.09
NetIncomeMargin 2023 -1.96
ReturnOnAssets TTM -0.14
ReturnOnAssets 2025 -0.02
ReturnOnAssets 2024 -0.02
ReturnOnAssets 2023 -0.13
ReturnOnEquity TTM -0.83
ReturnOnEquity 2025 -0.52
ReturnOnEquity 2024 -0.13
ReturnOnEquity 2023 -0.3
Recent news
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
2026-07-28 · CNW
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
2026-06-29 · PR Newswire
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
2026-03-25 · PR Newswire
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
2026-02-19 · Yahoo Finance
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
2026-01-20 · Yahoo Finance